HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

AVR

Anteris Technologies Global Corp.

Healthcare — Medical Instruments & Supplies

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

None 3 analysts
$7.61
$-0.16 (-2.06%)
Target: $15.33 (101.5%)

Price History

52-Week Range
Sign in to add AVR to a watchlist or set price alerts.

Fundamentals

Market Cap$763.16M
P/E Ratio (TTM)-
Forward P/E-8.00
EPS (TTM)$-2.22
Dividend Yield-
Profit Margin-
Revenue Growth-11.20%
ROE-59.21%
Debt/Equity1.34
Recommendation None
Analyst Target$15.33
Analysts3
Next Earnings -
Indexes -

Technical Indicators

RSI (14)25.0
Beta0.73
SMA 20$8.75
SMA 40$9.22
52-Week High$11.06
52-Week Low$2.99
50-Day Avg$9.17
200-Day Avg$6.35
Avg Volume$1.25M
Volume$1.03M

Performance Analysis

NEUTRAL

AVR presents a mixed picture with both positive and negative indicators.

~ Trading at 57% of its 52-week range.
+ RSI at 25.0 signals oversold conditions — a bounce may be ahead.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- Revenue declined 11.2% year-over-year.
~ Wall Street consensus is "none" from 3 analysts.
+ Average analyst target of $15.33 implies 101.5% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Aug 01, 2026 04:13 UTC

Back to Screener Export Report